CNSP News and Press, CNS Pharmaceuticals Inc. From 06/22/21

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious br...

Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition CNS’s focus has been on developing a means of ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, af...

As part of the annual reconstitution of the Russell stock indexes, CNS Pharmaceuticals (CNSP) has been selected to be added to the Russell 2000 Index effective June 25, 2021, after the close of the U.S. equity markets.Source: Press Release For further details see: CNS Pharmaceuticals to...

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index PR Newswire HOUSTON , June 17, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of n...

A recent study published in “ Neuro-Oncology ” has found that brain tumor global histology distribution differs significantly, which suggests inconsistencies in data quality and registration practices. Researchers examined data from more than 280 cancer registries that took p...

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal i...

In what many have described as groundbreaking work, a team of researchers based at University of Minnesota Twin Cities has demonstrated how the body’s immune cells can be engineered in order to navigate the physical barriers that make it hard for an individual’s immune system...

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to...

Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once th...